Valproic acid and celecoxib enhance the effect of temozolomide on glioblastoma cells

   Objective. To evaluate the survival of patients with recurrent glioblastoma receiving valproic acid and to study its impact in combination with temozolomide and celecoxib on tumor cells.

   Materials and methods. A retrospective analysis was conducted on data from patients diagnosed with glioblastoma (ICD-10 – C71) who received valproic acid as part of their comprehensive treatment and were reoperated on with recurrent glioblastoma. Tumor cells of the C6, U87 and T98G lines were used for the experimental study. Glioblastoma modeling was performed using Wistar rats. The study was approved by the ethics committee.

   Results. The median overall survival of patients with glioblastoma receiving valproic acid accounted for 22 months, compared to 13 months for patients not receiving valproic acid. In in vitro experiments, the half-maximal inhibitory concentration (IC50) of temozolomide for various tumor cell lines ranged from 435.3 to 844 μM; the IC50 of valproic acid for U87MG, T98G, and C6 cell lines comprised 1510, 3900, and 3600 μM, respectively; the IC50 of celecoxib for these tumor cell lines amounted to 30.1, 41.07, and 48.4 μM, respectively. Valproic acid significantly enhanced the antiglioma effect of temozolomide on U87 cell lines; the highest sensitivity to the action of celecoxib in combination with temozolomide was observed in C6 and T98G cell lines. The combination of valproic acid with celecoxib enhanced the antiglioma action of temozolomide both in vitro and in vivo, which was accompanied by a reduction in tumor volume (p < 0.05) and increased survival of experimental animals.

   Conclusion. The high antiglioma potential of the combination of valproic acid and celecoxib with temozolomide opens up prospects for optimizing existing treatment approaches for recurrent glioblastoma, thereby highlighting the need for further research. Valproic acid and celecoxib enhance the effects of temozolomide on glioblastoma cells.

1. McMahon DJ, Gleeson JP, O'Reilly S, Bambury RM. Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches. Medical Oncology. 2022;39(9):129. doi: 10.1007/s12032-022-01708-w

2. Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, Pineda B, Gutiérrez-Arroyo JL, Loras A, Gonzalez-Bonet LG, Martinez-Cadenas C, Estrela JM, Marqués-Torrejón MÁ. Glioblastoma Therapy: Past, Present and Future. International Journal of Molecular Sciences. 2024;25(5):2529. doi: 10.3390/ijms25052529

3. Vaz-Salgado MA, Villamayor M, Albarrán V, Alía V, Sotoca P, Chamorro J, Rosero D, Barrill AM, Martín M, Fernandez E, Gutierrez JA, Rojas-Medina LM, Ley L. Recurrent Glioblastoma : A Review of the Treatment Options. Cancers (Basel). 2023; 15(17):4279. doi: 10.3390/cancers15174279

4. Karve AS, Desai JM, Gadgil SN, Dave N, Wise-Draper TM, Gudelsky GA, Phoenix TN, DasGupta B, Yogendran L, Sengupta S, Plas DR, Desai PB. A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance. International Journal of Molecular Sciences. 2024;25(6):3217. doi: 10.3390/ijms25063217

5. Valerius AR, Webb LM, Sener U. Novel Clinical Trials and Approaches in the Management of Glioblastoma. Current Oncology Reports. 2024;26(5):439–465. doi: 10.1007/s11912-024-01519-4

6. Drexler R, Khatri R, Schüller U, Eckhardt A, Ryba A, Sauvigny T, Dührsen L, Mohme M, Ricklefs T, Bode H, Hausmann F, Huber TB, Bonn S, Voß H, Neumann JE, Silverbush D, Hovestadt V, Suvà ML, Lamszus K, Gempt J, Westphal M, Heiland DH, Hänzelmann S, Ricklefs FL. Temporal change of DNA methylation subclasses between matched newly diagnosed and recurrent glioblastoma. Acta Neuropathologica. 2024;147(1):21. doi: 10.1007/s00401-023-02677-8

7. Damanskienė E, Balnytė I, Valančiūtė A, Alonso MM, Stakišaitis D. Different Effects of Valproic Acid on SLC12A2, SLC12A5 and SLC5A8 Gene Expression in Pediatric Glioblastoma Cells as an Approach to Personalised Therapy. Biomedicines. 2022;10(5):968. doi: 10.3390/biomedicines10050968

8. Barciszewska AM, Belter A, Gawrońska I, Giel-Pietraszuk M, Naskręt-Barciszewska MZ. Cross-reactivity between histone demethylase inhibitor valproic acid and DNA methylation in glioblastoma cell lines. Frontiers in Oncology. 2022;12:1033035. doi: 10.3389/fonc.2022.1033035

9. Lombardi F, Augello FR, Artone S, Ciafarone A, Topi S, Cifone MG, Cinque B, Palumbo P. Involvement of Cyclooxygenase-2 in Establishing an Immunosuppressive Microenvironment in Tumorspheres Derived from ТМЗ-Resistant Glioblastoma Cell Lines and Primary Cultures. Cells. 2024;13(3):258. doi: 10.3390/cells13030258

10. van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC, Chang SM. Primary brain tumours in adults. Lancet. 2023;402(10412):1564–1579. doi: 10.1016/S0140-6736(23)01054-1

11. Lee PY, Wei YT, Chao KC, Chu CN, Chung WH, Wang TH. Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study. Journal of Cancer Research and Therapeutics. 2024;20(2):555–562. doi: 10.4103/jcrt.jcrt_750_22

12. Valiyaveettil D, Malik M, Joseph DM, Ahmed SF, Kothwal SA, Vijayasaradhi M. Effect of valproic acid on survival in glioblastoma: A prospective single-arm study. South Asian J Cancer. 2018 Jul-Sep;7(3):159–162. doi: 10.4103/sajc.sajc_188_17

13. Watanabe S, Kuwabara Y, Suehiro S, Yamashita D, Tanaka M, Tanaka A, Ohue S, Araki H. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma. Eur J Clin Pharmacol. 2017 Mar;73(3):357–363. doi: 10.1007/s00228-016-2167-1. Epub 2016 Nov 26. PMID: 27889835.

14. Ma S, Guo Z, Wang B, Yang M, Yuan X, Ji B, Wu Y, Chen S. A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them. Frontiers in Genetics. 2022;12:832627. doi: 10.3389/fgene.2021.832627

15. Sahu U, Barth RF, Otani Y, McCormack R, Kaur B. Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research. Journal of Neuropathology & Experimental Neurology. 2022;81(5):312–329. doi: 10.1093/jnen/nlac021

16. Liang SP, Wang XZ, Piao MH, Chen X, Wang ZC, Li C, Wang YB, Lu S, He C, Wang YL, Chi GF, Ge PF. Activated SIRT1 contributes to DPT-induced glioma cell parthanatos by upregulation of NOX2 and NAT10. Acta Pharmacologica Sinica. 2023;44(10):2125–2138. doi: 10.1038/s41401-023-01109-3

17. Chang HH, Chang YY, Tsai BC, Chen LJ, Chang AC, Chuang JY, Gean PW, Hsueh YS. A Selective Histone Deacetylase Inhibitor Induces Autophagy and Cell Death via SCNN1A Downregulation in Glioblastoma Cells. Cancers (Basel). 2022;14(18):4537. doi: 10.3390/cancers14184537